Medicines and vaccines have helped deliver improvements in patient health. History shows us the great advances we have made - today we continue to see the potential to eradicate disease and improve health outcomes when we invest in science and adopt and use new medicines.
Application of nanotechnologies: environmentNANOYOU
An introduction to the application of nanotechnologies in environment.
This chapter is part of the NANOYOU training kit for teachers.
For more resources on nanotechnologies visit: www.nanoyou.eu
The document discusses the application of nanotechnology in biosensors. It begins by defining nanotechnology and biosensors. Nanoparticles are gaining interest in biosensing applications due to their size-dependent properties. Standard procedures for detection are time-consuming, non-specific, costly, and require trained personnel. Nanoparticles can be used to develop micro/nanobiosensors that are fast, inexpensive, simple to use, efficient, and portable. Various types of nanoparticles and detection techniques using nanoparticles like fluorescence, inductively coupled plasma mass spectrometry, and potentiometric analysis are then described.
Pharmacogenomics is the study of how genetic factors influence individual responses to drugs. It aims to develop personalized drug therapies tailored to an individual's genetics. This could increase drug effectiveness to nearly 100% while decreasing side effects significantly by identifying genetic reasons for variances in drug response. However, barriers remain such as complexity in finding gene variations and limited drug alternatives. Overall, pharmacogenomics promises more rational drug development and safer, more accurate individualized treatment but overcoming challenges will require multidisciplinary efforts.
Pharmacogenomics is the study of how an individual's genetic profile affects their response to medications. It aims to provide the right drug at the right dose for the right patient by understanding genetic factors. Current applications include testing for genetic variants before prescribing certain drugs to avoid bad reactions. Challenges include accounting for both genetic and environmental influences on drug responses and protecting patient privacy. As understanding and technologies improve, pharmacogenomics may help develop new drugs and reduce trial-and-error prescribing.
This document discusses chemical carcinogens and their classification, mechanisms of action, and implications for workplace risk assessment and health surveillance. It describes the European Union system for classifying carcinogens into three categories based on evidence of cancer risks. Carcinogens can be genotoxic, causing cancer through DNA damage, or non-genotoxic, promoting cancer through other mechanisms like chronic injury. The document discusses approaches for setting occupational exposure limits depending on the carcinogen type and reviews challenges with medical surveillance given cancer latency periods. The key focus for worker health should be on preventing exposures through measures like exposure monitoring and minimizing synergistic risks rather than relying on screening.
This document discusses how nanosensors can be used in the food industry for safety and health purposes. Nanosensors offer improvements in selectivity, speed, and sensitivity compared to traditional methods for determining microbes, contaminants, pollutants, and food freshness. They can be placed in food packaging to rapidly detect pathogens. Wireless nanosensor networks are being developed to monitor food quality throughout the supply chain. The future of the food sector will rely on integrating nanosensor technology and the internet of things for producing and distributing safe nano-enabled products with little health or environmental impact.
The document discusses insulin, including its structure, gene location, processing in the body, and treatment of diseases related to insulin deficiency. Insulin is produced in the pancreas and enables cells to take up glucose. The human insulin gene is located on chromosome 11. Insulin is composed of two peptide chains linked by disulfide bonds. Treatment for insulin deficiency involves injection of insulin extracted from animals or recombinant human insulin produced using biotechnology. Recombinant human insulin is made through bacterial or yeast expression systems using vectors like plasmids or yeast artificial chromosomes.
Pharmacogenetics studies how a person's genetic makeup affects their response to drugs. It aims to develop personalized drug regimens to improve drug efficacy and safety. Every year in the US, adverse drug reactions cause 2 million people to experience side effects and over 100,000 die from reactions. Current drugs are only effective in 60% of the population. Pharmacogenetics uses genetic tests to determine a patient's risk of side effects or likelihood of response to a drug to help guide safer and more effective treatment decisions.
Application of nanotechnologies: environmentNANOYOU
An introduction to the application of nanotechnologies in environment.
This chapter is part of the NANOYOU training kit for teachers.
For more resources on nanotechnologies visit: www.nanoyou.eu
The document discusses the application of nanotechnology in biosensors. It begins by defining nanotechnology and biosensors. Nanoparticles are gaining interest in biosensing applications due to their size-dependent properties. Standard procedures for detection are time-consuming, non-specific, costly, and require trained personnel. Nanoparticles can be used to develop micro/nanobiosensors that are fast, inexpensive, simple to use, efficient, and portable. Various types of nanoparticles and detection techniques using nanoparticles like fluorescence, inductively coupled plasma mass spectrometry, and potentiometric analysis are then described.
Pharmacogenomics is the study of how genetic factors influence individual responses to drugs. It aims to develop personalized drug therapies tailored to an individual's genetics. This could increase drug effectiveness to nearly 100% while decreasing side effects significantly by identifying genetic reasons for variances in drug response. However, barriers remain such as complexity in finding gene variations and limited drug alternatives. Overall, pharmacogenomics promises more rational drug development and safer, more accurate individualized treatment but overcoming challenges will require multidisciplinary efforts.
Pharmacogenomics is the study of how an individual's genetic profile affects their response to medications. It aims to provide the right drug at the right dose for the right patient by understanding genetic factors. Current applications include testing for genetic variants before prescribing certain drugs to avoid bad reactions. Challenges include accounting for both genetic and environmental influences on drug responses and protecting patient privacy. As understanding and technologies improve, pharmacogenomics may help develop new drugs and reduce trial-and-error prescribing.
This document discusses chemical carcinogens and their classification, mechanisms of action, and implications for workplace risk assessment and health surveillance. It describes the European Union system for classifying carcinogens into three categories based on evidence of cancer risks. Carcinogens can be genotoxic, causing cancer through DNA damage, or non-genotoxic, promoting cancer through other mechanisms like chronic injury. The document discusses approaches for setting occupational exposure limits depending on the carcinogen type and reviews challenges with medical surveillance given cancer latency periods. The key focus for worker health should be on preventing exposures through measures like exposure monitoring and minimizing synergistic risks rather than relying on screening.
This document discusses how nanosensors can be used in the food industry for safety and health purposes. Nanosensors offer improvements in selectivity, speed, and sensitivity compared to traditional methods for determining microbes, contaminants, pollutants, and food freshness. They can be placed in food packaging to rapidly detect pathogens. Wireless nanosensor networks are being developed to monitor food quality throughout the supply chain. The future of the food sector will rely on integrating nanosensor technology and the internet of things for producing and distributing safe nano-enabled products with little health or environmental impact.
The document discusses insulin, including its structure, gene location, processing in the body, and treatment of diseases related to insulin deficiency. Insulin is produced in the pancreas and enables cells to take up glucose. The human insulin gene is located on chromosome 11. Insulin is composed of two peptide chains linked by disulfide bonds. Treatment for insulin deficiency involves injection of insulin extracted from animals or recombinant human insulin produced using biotechnology. Recombinant human insulin is made through bacterial or yeast expression systems using vectors like plasmids or yeast artificial chromosomes.
Pharmacogenetics studies how a person's genetic makeup affects their response to drugs. It aims to develop personalized drug regimens to improve drug efficacy and safety. Every year in the US, adverse drug reactions cause 2 million people to experience side effects and over 100,000 die from reactions. Current drugs are only effective in 60% of the population. Pharmacogenetics uses genetic tests to determine a patient's risk of side effects or likelihood of response to a drug to help guide safer and more effective treatment decisions.
The document discusses respiratory toxicology and covers several topics:
1. It describes the anatomy and functions of the upper and lower respiratory tract.
2. It explains the mechanisms of lung injury from toxic exposures, including oxidative stress and the role of antioxidants in the lung.
3. It covers several occupational and environmental lung diseases including pulmonary fibrosis, asthma, hypersensitivity pneumonitis, COPD, and lung cancer. It provides details on pulmonary fibrosis and the pathways involved in its development.
This document discusses regulatory frameworks for genetically modified crops at the national and international level. It provides an overview of:
- International efforts in food safety and principles of GM food safety assessment.
- How different countries/regions like the US, Canada, EU, Argentina, India, etc. have different agencies that regulate GM crop food safety and environmental release. The definitions of GMOs also vary between countries' laws.
- India's regulatory framework is established under the Environment Protection Act 1986. Key agencies involved include GEAC, RCGM and SBCC. Guidelines development involves expert consultation and consideration of research.
- The process for developing a GM crop in India involves extensive molecular, compositional and safety assessment
How nanotechnology affect biodiversity and ecosystem by shreya modiShreya Modi
This document discusses how nanotechnology can help address issues related to biodiversity and ecosystems. It describes how nanotechnology can help develop sustainable energy sources, treat wastewater, aid in oil spill cleanup, and enable better and more affordable medical treatment. The document provides multiple examples of how nanomaterials and nanoscale processes are already being used or explored to solve environmental problems and support human health and well-being while reducing environmental impacts.
The document discusses biosafety definitions, biological risk assessment, and guidelines for working with genetically modified organisms (GMOs). It defines biosafety as ensuring safety in using, handling, and disposing of biological organisms. Risk assessment of GMOs involves characterizing the agent, identifying hazards, evaluating risks, and applying management strategies. The guidelines classify GMOs based on their history of safe use and specify containment levels and approvals required for field testing.
Bioprocess modeling involves creating mathematical models of biological systems like cell cultures to improve process understanding and performance. Models are developed based on experimental data and can then be used to predict system behavior in different conditions. The modeling approach requires fewer experiments than the empirical approach but takes more time to develop models. Key steps in modeling include problem definition, model formulation, parameter estimation, validation and use of the model for design, optimization and control. Dynamic models are needed to represent transient system behavior important for control applications. Common modeling examples include reaction kinetics, bioreactor systems and sensor models.
Prostaglandins are hormone-like lipid compounds that are produced in various tissues and mediate important physiological functions. They were discovered in the 1930s and their chemical structures were elucidated in the 1950s. Sune Bergström, Bengt Samuelsson, and John Vane conducted seminal research in the 1960s and 1970s on prostaglandin biosynthesis, metabolism, and physiological roles. Their work showed that prostaglandins are derived from fatty acids and mediate processes like inflammation and reproduction. Bergström, Samuelsson, and Vane received the 1982 Nobel Prize in Physiology or Medicine for their discoveries concerning prostaglandins.
Monoclonal Antibodies As Therapeutic Agents In Oncology Anddrmisbah83
This document discusses monoclonal antibodies as therapeutic agents for cancer and antibody gene therapy. It describes how monoclonal antibodies work to target cancer cells, lists some common monoclonal antibody drugs approved for cancer treatment, and discusses potential side effects. It also introduces the concept of using antibody gene therapy as a new strategy for cancer treatment by delivering antibody genes directly to tumors using vectors like adenovirus or mesenchymal stem cells.
Application of industrial BiotechnologyGhassan Hadi
The document discusses industrial biotechnology and microbial technology. Microbial technology uses microbes to produce products and services of economic value. It involves isolating microbes, screening them for product formation, improving yields, culturing and harvesting products. Microbes are used to produce metabolites, treat waste, control pests and pathogens, and ferment food. They can enhance nutrient availability as biofertilizers. Microbes also recover metals from ores and desulfurize coal. New technologies allow ethanol to be produced from crop residues rather than just grains. Industrial biotechnology and microbial technology have benefits like low substrate input, high output, environmental friendliness, renewability, and increased efficiency.
The document discusses various applications of nanotechnology in biomedical fields such as medicine and healthcare. It describes how nanotechnology can be used to develop targeted drug delivery systems, lab-on-chip devices for disease detection and diagnosis, bionanomaterials for medical applications, and nanoscale machines and sensors. It also discusses how nanotechnology enables more precise detection and treatment of diseases like cancer at the molecular level with fewer side effects.
Pharmacogenetics is the study of how genetic variations affect drug metabolism and response. This document discusses key concepts in pharmacogenetics including:
- Pharmacogenetics has been studied for over 40 years to understand how heritability impacts drug response.
- Goals include maximizing drug efficacy while minimizing toxicity and predicting patient response.
- Early examples focused on single genes but most traits are now understood to be polygenic.
- The CYP2D6 enzyme metabolizes many drugs like tamoxifen and genetic variants can make patients poor or intermediate metabolizers, impacting drug levels and response.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The document discusses the importance of manufacturing to the UK pharmaceutical industry and the life sciences sector. It outlines the goals of the Medicines Manufacturing Industry Partnership (MMIP) in making the UK an attractive location for medicines manufacturing through initiatives like skills development programs. The document also notes industry's significant financial contributions to the NHS through the Pharmaceutical Price Regulation Scheme, and the importance of ensuring a regulatory framework that supports innovation as the UK leaves the EU.
The document discusses various ways that the pharmaceutical industry is working with patients and healthcare professionals to increase patient involvement in medicine development. It provides examples of patient groups being more involved in clinical trials and discussions earlier in the process. It also discusses efforts by the industry to increase transparency, such as publishing payments to healthcare professionals and sharing clinical trial data with researchers. There has been steady improvement in disclosure rates for clinical trial results.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
The document provides information on recent updates to the EU Falsified Medicines Directive and its requirements for safety features on medication packaging to help prevent falsified medicines. It discusses the growing problem of falsified medicines in Europe, the goals of the Falsified Medicines Directive to strengthen regulation of the pharmaceutical supply chain, and the delegated regulation outlining technical specifications for unique identifiers and anti-tampering devices that must be implemented by February 2019. It also addresses the roles and responsibilities of various stakeholders including marketing authorization holders, manufacturers, wholesalers, pharmacies and regulatory authorities in complying with the new regulations.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Bilcare GCS provides end-to-end clinical trial material supply chain services including packaging, labeling, storage, distribution, and returns/destruction. It has facilities in India and a global depot network to support clinical trials worldwide. Services include primary and secondary packaging, comparator sourcing, IVRS/IWRS, logistics and supply chain management, and QA/QC through qualified professionals and compliant facilities.
The document discusses Turkey's track and trace system for pharmaceuticals and the system implemented by Nobel Pharma. It provides an overview of the Turkish regulations, Nobel's system which tracks over 3 billion product units annually using barcodes and a centralized database. The system provides notifications at each stage of production, distribution and sale. It has provided benefits such as reduced fraud and better inventory and recall management. Lessons learned include involving all stakeholders from the start and spending more time piloting the system.
The document discusses respiratory toxicology and covers several topics:
1. It describes the anatomy and functions of the upper and lower respiratory tract.
2. It explains the mechanisms of lung injury from toxic exposures, including oxidative stress and the role of antioxidants in the lung.
3. It covers several occupational and environmental lung diseases including pulmonary fibrosis, asthma, hypersensitivity pneumonitis, COPD, and lung cancer. It provides details on pulmonary fibrosis and the pathways involved in its development.
This document discusses regulatory frameworks for genetically modified crops at the national and international level. It provides an overview of:
- International efforts in food safety and principles of GM food safety assessment.
- How different countries/regions like the US, Canada, EU, Argentina, India, etc. have different agencies that regulate GM crop food safety and environmental release. The definitions of GMOs also vary between countries' laws.
- India's regulatory framework is established under the Environment Protection Act 1986. Key agencies involved include GEAC, RCGM and SBCC. Guidelines development involves expert consultation and consideration of research.
- The process for developing a GM crop in India involves extensive molecular, compositional and safety assessment
How nanotechnology affect biodiversity and ecosystem by shreya modiShreya Modi
This document discusses how nanotechnology can help address issues related to biodiversity and ecosystems. It describes how nanotechnology can help develop sustainable energy sources, treat wastewater, aid in oil spill cleanup, and enable better and more affordable medical treatment. The document provides multiple examples of how nanomaterials and nanoscale processes are already being used or explored to solve environmental problems and support human health and well-being while reducing environmental impacts.
The document discusses biosafety definitions, biological risk assessment, and guidelines for working with genetically modified organisms (GMOs). It defines biosafety as ensuring safety in using, handling, and disposing of biological organisms. Risk assessment of GMOs involves characterizing the agent, identifying hazards, evaluating risks, and applying management strategies. The guidelines classify GMOs based on their history of safe use and specify containment levels and approvals required for field testing.
Bioprocess modeling involves creating mathematical models of biological systems like cell cultures to improve process understanding and performance. Models are developed based on experimental data and can then be used to predict system behavior in different conditions. The modeling approach requires fewer experiments than the empirical approach but takes more time to develop models. Key steps in modeling include problem definition, model formulation, parameter estimation, validation and use of the model for design, optimization and control. Dynamic models are needed to represent transient system behavior important for control applications. Common modeling examples include reaction kinetics, bioreactor systems and sensor models.
Prostaglandins are hormone-like lipid compounds that are produced in various tissues and mediate important physiological functions. They were discovered in the 1930s and their chemical structures were elucidated in the 1950s. Sune Bergström, Bengt Samuelsson, and John Vane conducted seminal research in the 1960s and 1970s on prostaglandin biosynthesis, metabolism, and physiological roles. Their work showed that prostaglandins are derived from fatty acids and mediate processes like inflammation and reproduction. Bergström, Samuelsson, and Vane received the 1982 Nobel Prize in Physiology or Medicine for their discoveries concerning prostaglandins.
Monoclonal Antibodies As Therapeutic Agents In Oncology Anddrmisbah83
This document discusses monoclonal antibodies as therapeutic agents for cancer and antibody gene therapy. It describes how monoclonal antibodies work to target cancer cells, lists some common monoclonal antibody drugs approved for cancer treatment, and discusses potential side effects. It also introduces the concept of using antibody gene therapy as a new strategy for cancer treatment by delivering antibody genes directly to tumors using vectors like adenovirus or mesenchymal stem cells.
Application of industrial BiotechnologyGhassan Hadi
The document discusses industrial biotechnology and microbial technology. Microbial technology uses microbes to produce products and services of economic value. It involves isolating microbes, screening them for product formation, improving yields, culturing and harvesting products. Microbes are used to produce metabolites, treat waste, control pests and pathogens, and ferment food. They can enhance nutrient availability as biofertilizers. Microbes also recover metals from ores and desulfurize coal. New technologies allow ethanol to be produced from crop residues rather than just grains. Industrial biotechnology and microbial technology have benefits like low substrate input, high output, environmental friendliness, renewability, and increased efficiency.
The document discusses various applications of nanotechnology in biomedical fields such as medicine and healthcare. It describes how nanotechnology can be used to develop targeted drug delivery systems, lab-on-chip devices for disease detection and diagnosis, bionanomaterials for medical applications, and nanoscale machines and sensors. It also discusses how nanotechnology enables more precise detection and treatment of diseases like cancer at the molecular level with fewer side effects.
Pharmacogenetics is the study of how genetic variations affect drug metabolism and response. This document discusses key concepts in pharmacogenetics including:
- Pharmacogenetics has been studied for over 40 years to understand how heritability impacts drug response.
- Goals include maximizing drug efficacy while minimizing toxicity and predicting patient response.
- Early examples focused on single genes but most traits are now understood to be polygenic.
- The CYP2D6 enzyme metabolizes many drugs like tamoxifen and genetic variants can make patients poor or intermediate metabolizers, impacting drug levels and response.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
Trailblazing scientists who are the backbone of our industry. These are the people that discover the molecules and develop the medicines to tackle the toughest diseases we face in society.
The document discusses the importance of manufacturing to the UK pharmaceutical industry and the life sciences sector. It outlines the goals of the Medicines Manufacturing Industry Partnership (MMIP) in making the UK an attractive location for medicines manufacturing through initiatives like skills development programs. The document also notes industry's significant financial contributions to the NHS through the Pharmaceutical Price Regulation Scheme, and the importance of ensuring a regulatory framework that supports innovation as the UK leaves the EU.
The document discusses various ways that the pharmaceutical industry is working with patients and healthcare professionals to increase patient involvement in medicine development. It provides examples of patient groups being more involved in clinical trials and discussions earlier in the process. It also discusses efforts by the industry to increase transparency, such as publishing payments to healthcare professionals and sharing clinical trial data with researchers. There has been steady improvement in disclosure rates for clinical trial results.
The future of healthcare is an exciting one. With innovations in genomics, healthcare data, advanced therapies and innovative technologies, our industry will continue to progress and provide hope to people so they can live longer, healthier and productive lives.
The document provides information on recent updates to the EU Falsified Medicines Directive and its requirements for safety features on medication packaging to help prevent falsified medicines. It discusses the growing problem of falsified medicines in Europe, the goals of the Falsified Medicines Directive to strengthen regulation of the pharmaceutical supply chain, and the delegated regulation outlining technical specifications for unique identifiers and anti-tampering devices that must be implemented by February 2019. It also addresses the roles and responsibilities of various stakeholders including marketing authorization holders, manufacturers, wholesalers, pharmacies and regulatory authorities in complying with the new regulations.
The UK is at the forefront of the global pharmaceutical industry. As well as developing new medicines for many diseases, the pharmaceutical industry in the UK provides many other benefits to the British economy, including income, employment, expertise and major investment.
These slides offer a useful, referenced resource for members and visitors to our website who wish to share the story about the value of medicines. They complement existing resources available on the ABPI website and will be updated regularly as the ABPI updates other data and content.
Bilcare GCS provides end-to-end clinical trial material supply chain services including packaging, labeling, storage, distribution, and returns/destruction. It has facilities in India and a global depot network to support clinical trials worldwide. Services include primary and secondary packaging, comparator sourcing, IVRS/IWRS, logistics and supply chain management, and QA/QC through qualified professionals and compliant facilities.
The document discusses Turkey's track and trace system for pharmaceuticals and the system implemented by Nobel Pharma. It provides an overview of the Turkish regulations, Nobel's system which tracks over 3 billion product units annually using barcodes and a centralized database. The system provides notifications at each stage of production, distribution and sale. It has provided benefits such as reduced fraud and better inventory and recall management. Lessons learned include involving all stakeholders from the start and spending more time piloting the system.
Parbat Singh Sodha is seeking a career that allows him to utilize and develop his skills in a professional environment and keep his knowledge updated. He has a B.Ed from M.G.S University and worked in multiple front office roles for hotel chains from 2008-2015, most recently as a front office supervisor. He has strong computer skills including Microsoft Office and enjoys challenges.
This slide deck gives background to, and an update on, the Falsified Medicines Directive and Delegated Regulation. More more information about the FMD, please visit: http://www.abpi.org.uk/our-work/falsified-medicines-directive/Pages/default.aspx
Top10 Sales Transformation Keys to SuccessDSG Consulting
We’ve watched hundreds of B2B organizations succeed as well as fail at Sales Transformation. Sales Transformation cannot happen in organizations where leaders underestimate the level of change required or underinvest in Sales. Here’s our Top 10 list of how to get change management with Sales Enablement right.
The world's leading social selling teams share the blueprints that led to success within their organizations. These blueprints provide a template that other Sales teams can follow to generate awareness and sponsorship, educate and train on the frontline, and ultimately create long term accountability.
The Turkish “Pharmaceuticals Track and Trace System” (generally abbreviated as ITS) defines the infrastructure constructed to track and trace all units belonging to each pharmaceutical product in Turkey. ITS is an application of the infrastructure that is known as “Track & Trace” in the literature.Datamatrix code is used instead of formerly used barcode to ensure the uniqueness of the units. Every single step and action of the unit in the supply chain is gathered by web services to provide the traceability.
It is mandatory for every medicine or pharma packaging to have a unique serial code or UID. Project is to build a web application that will provide tracking capabilities for the UID for pharma packaging of drugs. The track feature (TRACK n trace) will track the UID of each package by using vision based scanners, RFIDs, etc. and store the data into a local server. The server will be synced daily with a global server (we are looking for cloud based hosting platforms such as Windows Azure or amazon web services). We have to build the trace functionality (Track n TRACE) by building a web interface where a person with the UID can trace the shipment.
We have to keep historical records for as long as 10 years and build logic on basis of the UID state. We have to provide the details from the database as in when was this package manufactured, when was it shipped, etc. If the UID entered is faulty for example; it wasn’t ever manufactured or if it is over its expiration date then we have to generate corresponding errors and also maintain a log of such entries and send notification to the admins with details of IP, Geography or where the error generated.
The document describes Turkey's Pharmaceutical Track and Trace System (ITS) which was implemented to address issues like counterfeit drugs and drug theft. The key aspects of the system include:
1) Serializing each drug unit with a unique DataMatrix code for tracking through the supply chain from manufacturer to patient.
2) Gathering data on each drug unit at each step to enable full tracking and traceability through electronic pedigrees.
3) Centralizing the system for more efficient data management compared to document-based e-pedigree systems.
4) Producing statistics on over 40,000 stakeholders and over 6.5 billion drug units tracked to date, demonstrating the system's effectiveness.
The document discusses strategies for adapting sales processes to changing customer and market dynamics. It recommends 1) creating systems of engagement to interact with customers throughout their journey, 2) selling business outcomes rather than just products, 3) differentiating at multiple levels to stand out from competitors, 4) helping customers see value and connect solutions to their needs, and 5) building an adaptive, growth-oriented culture. The overall message is that companies must evolve their approaches to remain relevant as customer expectations and technologies change.
Prescription Medicines: International Costs in ContextPhRMA
Our new Prescription Medicines: International Costs in Context explains how medicines benefit patients, health care systems, and the global economy. Advances in treatment are tacking some of the world’s greatest public health challenges. These treatments provide critical savings for health care systems by reducing the need for more costly services. What’s more is the profound impact that biopharmaceutical companies have on the global economy, including the creation of high-skill jobs, R&D investment, and medicines that improve worker productivity.
This document provides information about Dr. Paul Cornes and his work in oncology. It discloses that Dr. Cornes receives a salary from the UK National Health Service and has received honoraria from several pharmaceutical companies. The bulk of the document discusses the costs of cancer to individuals and societies and highlights both challenges and areas of progress in cancer treatment, including improved survival rates due to innovations in targeted therapies and monoclonal antibodies.
Multidrugresistant tuberculosis
Among the most menacing forms of MDR is multidrug
resistant tuberculosis (MDR-TB). WHO estimates that
were about 450,000 new cases and 170,000 deaths from
MDR-TB in 2012. The number of cases reported to
WHO rose by an alarming 35% between 2011 and 2012,
although this probably mostly reflects increased recognition
and reporting. Over half the new cases were in India,
China or the Russian Federation.3
This issue of Homeopathy features a paper by Dr Kusum
Chand and colleagues reporting a randomized, double blind,
placebo-controlled clinical trial of individualized homeopathic
treatment or placebo in addition to standard antituberculous
chemotherapy as specified by the Indian Revised
National Tuberculosis Control Program, for MDR-TB
This document discusses the emerging field of personalized or tailored medicine. It begins with an introduction to personalized medicine, defining it as tailoring medical treatments to an individual's characteristics. The document then covers the history and driving factors behind personalized medicine. It discusses the goals and benefits of personalized medicine, as well as some limitations. Potential applications discussed include pharmacogenetics, pharmacometabonomics, and cancer management. Several examples of personalized cancer treatments and diagnostics are provided. The document emphasizes that a one-size-fits-all approach to medicine is often ineffective and can cause harm, whereas personalized medicine aims to provide each patient with the right treatment.
Herbal Medicine for Cancer Treatment: Main Force or Supplement_Crimson Publis...CrimsonpublishersCancer
The Estimated numbers of new cancer cases and deaths in 2020 will be an estimated. 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States and there were 17 million new cases of cancer worldwide in 2018 [1]. The four most common cancers occurring worldwide are lung, female breast, bowel and prostate. A person’s risk of developing cancer depends on different factors, including age, genetics, and exposure to some potentially known carcinogens and those which are believed to be carcinogenic. Some avoidable lifestyle factors including smoking can increase cancer risk. However, cancer risk factors are similar worldwide. Insufficient exercise, alcohol, imbalanced diet, and obesity, and various infections account for a considerable proportion of cancers worldwide. Prevalence of any one of the risk factors varies in different ethnic groups and can vary by region and country, which contributes to variation of cancer incidence rates of the common types of cancer worldwide.
Major Neglected Tropical Diseases (NTD)Updesh Yadav
This report analyzes the growth of research on neglected tropical diseases (NTDs) over the past two decades using data from scientific publications. It finds that while NTDs impact over a billion people and cause over 500,000 deaths per year, they received very little research funding and attention historically compared to other global health issues. However, there has been growing recognition of NTDs in recent years, driven by advocates and new funding from organizations like the Bill & Melinda Gates Foundation. A landmark 2012 meeting saw over $785 million pledged towards NTD research and treatment, demonstrating new commitments to addressing these neglected issues. The data shows significant increases in scientific publications on NTDs in the past decade, though research is still disproportionately low relative to
Dr Paul Cornes has received salary from the UK National Health Service and honoraria from several pharmaceutical companies including Roche, Janssen, Sandoz, Lilly, European Generics Association, Teva, and Hospira. The document discusses the increasing cost of cancer drugs and argues that greater use of generics and biosimilars can help contain costs while maintaining treatment effectiveness. It provides examples showing that in the US, increased generic drug use has saved over $1 trillion in healthcare costs in the past decade through lower prices.
The document discusses the role of diagnostics in preventing antimicrobial resistance (AMR). It notes that inappropriate antibiotic use is fueling the emergence of AMR globally and reducing treatment options. Currently 700,000 deaths per year are due to drug-resistant infections and this could rise to 10 million by 2050. Diagnostics can play a key role in optimizing antibiotic use, preserving new drugs, and enabling surveillance. The document outlines FIND's strategy to develop and promote rapid diagnostic tests to improve rational antibiotic use in low-resource settings and preserve antibiotics by enabling more targeted treatment.
Nature medicine top ten advancements in biomedicine in 2020DoriaFang
In the field of biomedicine, which is closely related to human health, many innovative therapies have matured this year and promoted medical progress. Recently, the authoritative academic journal "Nature Medicine" published a series of articles reviewing ten remarkable advancements in 2020.
Dr Dev Kambhampati | FDA- Paving the Way for Personalized MedicineDr Dev Kambhampati
This document discusses personalized medicine from a regulatory perspective. It begins by defining personalized medicine as tailoring medical treatment to an individual's characteristics, needs, and preferences. The concept has existed for hundreds of years but recent advances in genomics, medical imaging, and other areas now enable a more personalized approach. The FDA plays a unique role in advancing personalized medicine by helping to bring these new medical products to market and evolving its regulatory processes in response to scientific developments. The document outlines FDA's efforts to define regulatory pathways, collaborate on research, and apply new knowledge to product reviews to help usher in this new era of individualized healthcare.
10 years of biosimilars who benefits (1)Luis Sales
This document discusses the benefits of biosimilars over the past 10 years. It notes that biosimilars have improved patient access to treatments by increasing competition and reducing costs for healthcare systems. However, it also acknowledges concerns about the potential risks of biosimilars. Going forward, it suggests the future of biosimilars depends on continued evidence that they provide the same efficacy and safety outcomes as reference drugs.
Scientists at St George’s, University of London and the University of Manchester have received additional funding to explore a new class of experimental drugs called Allergen Delivery Inhibitors (ADIs) that block allergic reactions before symptoms occur. Unlike existing medications, ADIs target the substances that trigger allergies and asthma attacks directly, providing relief for those already suffering and reducing the risk of minor allergies becoming more serious. The funding will allow the researchers to further explore a promising chemical series identified previously and identify a lead compound for drug development to treat asthma and allergies like rhinitis, which affect over 100 million people globally.
5
Cancer
Student Name
University
Professor
Course
Date
Cancer
Cancer is a major cause of morbidity and mortality globally, accounting for 9.5 million deaths as of 2018. Thyroid Cancer is one of the most frequent endocrine malignancies, contributing to 3.4 percent of all cancers in the United States each year Indini et al.(2022). While there has been significant progress in the development of new cancer treatments and the increase in the use of anticancer drugs over the past few years, the side effects of these drugs can be severe and sometimes life-threatening. However, there is still a lack of evidence regarding their efficacy and safety. As a result, it is critical to assess the benefits and risks of these medications before hospitals use them to treat cancer patients. This literature review aims to assess the benefits and risks of anticancer medicines in patients with advanced cancer. This literature study will aid in a deeper understanding of these medications and their prospective usage in cancer care.
Similarities
Methodology
Silaghi et al. (2022) and Bachelard et al. (2021) conducted systematic reviews and meta-analyses to investigate the risks and advantages of anticancer medications in patients with advanced cancer, as well as potential causes of resistance to such treatments. Both investigations looked for clinical trials in English written between the years 2000 through 2021 and followed the PRISMA criteria. Indini et al. (2022) employed a different technique conducting a systematic review of the function of the mTOR and NAD pathways in malignancy treatment, progression, and resistance. This study searched Google Scholar, Scopus, PubMed, and Embase for English language papers published between 2000 through 2021.
Findings
Anticancer medication usage was related to a considerable risk of death in advanced cancer patients, according to Silaghi et al. (2022) and Bachelard et al. (2021). However, the authors discovered that these medications were linked to a considerable increase in the likelihood of surviving for at least a year. Furthermore, the researchers discovered that using these medications was related to a considerable increase in the likelihood of living for more than five years. Their findings differed significantly from those of Indini et al. (2022), who discovered that the mTOR and NAD paths are responsible for drug resistance in malignant cells. Furthermore, the authors discovered that these pathways might be possible targets for future treatment methods.
Recommendations
Targeted therapy is recommended by Bachelard et al. (2021), Indini et al. (2022), and Silaghi et al. (2022) as potential therapeutic choices for individuals with advanced cancer who have completed standard-of-care treatment. They also emphasize the necessity of knowing medication resistance mechanisms to design more effective targeted therapeutics. Furthermore, they underline the need for trustworthy biomarkers in guiding treatment deci.
The document discusses the history and progress of medicine and genomics over the past century. It describes how the human genome was sequenced between 2000-2003 and how this sparked the rise of omics technologies and new databases. It also discusses how microarray testing in 2012 revealed two subtypes of diffuse large B cell lymphoma that respond differently to treatments, representing an early achievement of precision medicine. The document advocates that clinical lab scientists help make precision diagnostic tests more widely accessible and efficient to improve health outcomes.
Rare Diseases: A Report on Orphan Drugs in the PipelinePhRMA
Rare diseases, when taken together, are not that rare at all. In fact, according to the National Institutes of Health (NIH), 30 million Americans have one of the nearly 7,000 diseases that are officially deemed “rare” because alone they each affect fewer than 200,000 people in the United States.
Global Medical Cures™ | Paving way for Personalized Medicine (2013) Global Medical Cures™
Global Medical Cures™ | Paving way for Personalized Medicine (2013)
DISCLAIMER-
Global Medical Cures™ does not offer any medical advice, diagnosis, treatment or recommendations. Only your healthcare provider/physician can offer you information and recommendations for you to decide about your healthcare choices.
Precision medicine aims to customize medical treatments and products to an individual based on their genetic, environmental and lifestyle factors. Advances in genomics from projects like the Human Genome Project have increased understanding of human genetic diversity and potential for individualized healthcare. This has led to a rise in precision medicine approaches and companies offering personalized health services like genetic testing and microbiome analysis. Public sector initiatives are also emerging like an ingestible pill to diagnose gut disorders and large research programs to study disease prevention and treatment through precision approaches. Precision medicine has significant implications for diseases like cancer and holds potential to better address chronic conditions, though regulatory considerations will be important as innovation progresses rapidly.
The document discusses enhancing quality of life as an important goal for cancer treatment. It notes that while treatments have increased survival rates, they can also cause chronic health issues for survivors that reduce quality of life. More research is needed to better understand and prevent these toxic side effects, through identifying biomarkers and mitigation strategies. The authors call for increased priority and resources for quality of life research to both improve existing treatments and enable more patients to benefit from new therapies.
Personalized Medicine: A Utilization In Pharmaceutical Field.(A Review) Makrani Shaharukh
Personalized Medicine (PM) is an emerging exercise of medicine that uses a person‟s genetic summary to monitor judgments made in favor to the diagnosis, inhibition and treatment of diseases. Personalized medicine is presence innovative through data from the Human Genome Project. It is initial to complete its aim of “the right therapy to the right patient at the right time”. Currently PM is moving us closer to more exact, predictable and powerful medication tailored for an individual patient. By the way the genomic data is the dynamic force late PM. Combined understanding of genetics is approving us to provide greater diagnoses, safer medication advising, and more effective treatment of the diseases and conditions that have affected us throughout history. This review focus on various aspects of personalized medicine.
Histololgy of Female Reproductive System.pptxAyeshaZaid1
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Mercurius is named after the roman god mercurius, the god of trade and science. The planet mercurius is named after the same god. Mercurius is sometimes called hydrargyrum, means ‘watery silver’. Its shine and colour are very similar to silver, but mercury is a fluid at room temperatures. The name quick silver is a translation of hydrargyrum, where the word quick describes its tendency to scatter away in all directions.
The droplets have a tendency to conglomerate to one big mass, but on being shaken they fall apart into countless little droplets again. It is used to ignite explosives, like mercury fulminate, the explosive character is one of its general themes.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Cosmetology and Trichology Courses at Kosmoderma Academy PRP (Hair), DR Growt...
Chapter 1: Medicines and vaccines
1. 9
1. UCL School of Pharmacy: Affording the Future? The role of cost effectiveness thresholds in determining NHS patient access to high quality care in the post-Brexit era
http://www.ucl.ac.uk/pharmacy/departments/practice-policy
Medicines and vaccines –have
helped deliver improved patient
health and overall survival1
2. Improved outcomes for patients
Patients all over the world are
living longer, healthier and more
productive lives, thanks to
innovative medicines developed
by biopharmaceutical companies1
1. Jackman, D. The Value of Pharmaceutical Products to Patients and the Healthcare System Versus the Cost http://blog.cslbehring.com/2016/01/value-versus-cost//
10
3. Effective vaccinations have contributed to the fight
against communicable diseases
In England,
infant deaths
declined 79%
from 2012 to 2013 as a result
of a maternal pertussis
vaccination program.2
1. Boccalini 2013 .Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy. Human Vaccines & Immunotherapies.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3899148/
2. Amirthalingam 2014 .Effectiveness of maternal pertussis vaccination in England .The Lancet. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60686-3/abstract
3. Office for National Statistics. http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/birthsummarytablesenglandandwales/2015
4. National Records of Scotland. http://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-theme/vital-events/general-publications/vital-events-reference-tables/2014/section-3-births.
5. Northern Ireland Research and Statistics Agency. http://www.nisra.gov.uk/demography/default.asp8.htm
Italy was the first
industrialised country
to introduce a programme
for routine vaccination
against hepatitis B virus
(HBV); this program
led to an
82% decline
in the incidence
of HBV
from 1991
to 2010.1
In 2015 the UK was the first
country
in the world to offer a
vaccine that will help
protect babies
against
meningitis B
as part of a national
childhood immunisation
programme. There
around 800,000
babies born each
year in the UK.3,4,5
11
4. Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen
in the USA
20102005 2006 2007 20092008 2011 2012 2013 2014
12
2005:
First new kidney cancer treatment in
over a decade
3 new therapies for diabetes
2008:
A new type of treatment for Crohn’s
disease
The first Rx for symptoms of
Huntington’s disease
2007:
New class of medicines to treat
high blood pressure
First treatment for fibromyalgia
2009:
First treatment for peripheral T-cell lymphoma
First new Rx for gout in 40 years
2006:
First vaccine for the prevention of cervical
cancer
First Rx for chronic chest pain in 10 years
First once-a-day HIV medicine
2010:
2 new multiple sclerosis medicines
First therapeutic cancer vaccine
2011:
First lupus medicine in 50 years
2 new personalised medicines
2012:
First drug to target root cause of
cystic fibrosis
First drug to treat Cushing’s disease
2013:
2 new personalised medicines to treat the
most dangerous forms of skin cancer
A new oral treatment for multiple sclerosis
2014:
Oral treatments for hepatitis C provide cure rates
upwards of 90%
17 new drugs to treat patients with rare diseases
2015
2015:
2 new drugs for difficult-to-treat forms of high
cholesterol
New cystic fibrosis drug for patients with genetic
mutation that is the most common of the disease
12
5. 1. FDA Approves New Treatment for Advanced Kidney Cancer. FDA (2005)
2. FDA approved Diabetes Medicines. FDA (2005)
3. FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Diseases in Females Caused by Human Papillomavirus. FDA (2006)
4. FDA Approves New Treatment for Chest Pain. (2006)
5. FDA Approves the First Once-a-Day Three-Drug Combination Tablet for Treatment of HIV-1. FDA (2006)
6. FDA Approves New Beta Blocker to Treat High Blood Pressure. FDA (2007)
7. FDA Approves First Drug for Treating Fibromyalgia. FDA (2007)
8. FDA Approves Cimzia to Treat Crohn's Disease. FDA. (2008)
9. FDA Approves First Drug for Treatment of Chorea in Huntington's Disease. FDA. (2008)
10. FDA Approves First Drug for Treatment of Peripheral T-cell Lymphoma. FDA (2009)
11. FDA Approves Colchicine for Acute Gout, Mediterranean Fever. FDA (2009)
12. FDA approves first oral drug to reduce MS relapses. FDA (2010)
13. FDA Approves a Cellular Immunotherapy for Men with Advanced Prostate Cancer . FDA (2010)
14. FDA approves Benlysta to treat lupus. FDA (2011)
15. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer- FDA (2011)
16. FDA approves Kalydeco to treat rare form of cystic fibrosis. FDA (2012).
17. FDA approves Korlym for patients with endogenous Cushing’s syndrome. FDA (2012)
18. FDA approves two drugs, companion diagnostic test for advanced skin cancer. FDA (2013)
19. FDA approves new multiple sclerosis treatment. FDA (2013)
20. FDA approves first combination pill to treat hepatitis C. FDA (2014)
21. FDA Novel new drugs summary. FDA. (2014)
22. FDA Novel drugs 2015 summary. FDA. (2015)
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen
in the USA - accompanying referencing
13
6. The pharmaceutical research and development process
takes time
From medicine discovery
to EMA approval,
developing a new
medicine on average
takes at least 10 years
and can cost £1.15
billion1,2
Just 10-15% of
molecules that enter
clinical testing are
approved3
1. Paul S, Nature Reviews Drug Discovery 9 203-214 (March 2010) | doi:10.1038/nrd3078 In 2010 prices based on Bank of England exchange rate
2. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014 Jan 9;32(1):40–51.
3. Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004 Aug;3(8):711–6.
14
7. As of 2016, 7000 new medicines are in development
globally across a number of different diseases
1. Outcomes-driven sustainable healthcare. http://www.efpia.eu/topics/innovation/outcomes
2. Prescription Medicines: Costs in Context. August 2016. http://www.phrma.org/report/prescription-medicines-costs-in-context (references all figures in graphic)
Cardiovascular
disorders2
599 159
HIV/AIDS2
1,256
Infectious
diseases2
1,329
Neurological
disorders2
1,813
Cancers2
475
Diabetes2
1,120
Immunological
disorders2
511
Mental health
disorders2
With over 7000 new medicines in development, the exciting new wave of medical innovation will play a key role in
addressing the challenges faced by patients and healthcare systems1.
15
8. Discovering new technologies to develop
new medicines is central to our industry
Working in partnership
New science is so complex that no
organisation holds all the knowledge to make
new medicines alone.
We increasingly work in partnership to share
expertise to develop new medicines more
quickly.
SGC – a partnership of industry partners and
world-leading academics, working to understand
the function of parts of our genetic code that have
previously not been studied. This helps accelerate
our understanding of the body in both health and
disease, highlighting possible targets for new
medicines.1
Open targets – a partnership between UK
academics and biopharma companies looking to
associate diseases with molecules in the body
which may could be targeted by new medicines.2
Cutting edge science and
technology
Companies use cutting edge science
and technology to accelerate the
discovery and development of
innovative medicines
Clustered regularly interspaced short
palindromic repeats (CRISPR) – is a new
technology that lets scientists precisely edit
genetic code. It can be used in many
different ways by our industry to help
discover new medicines. For example it
can be used to create cell lines which
model an individual’s cancer, which can
help scientists develop new personalised
therapies.3
Basic biology to new
medicines
Industry scientists work in partnership
with others to understand diseases,
and translate this into new medicines
NEWMEDS IMI project – companies and
academics work to create new models of
schizophrenia and depression, to better
understand the diseases, and help identify
possible mechanisms to treat them.4
U-Biopred IMI project – companies and
academics work to divide asthma patients
into groups based on the different molecular
basis of their illness. This will help scientists
and doctors
understand why patients respond different to
treatment, and develop
news therapies.5
1. SGC (2016). Pioneering Science to Inspire Pioneering Medicines. http://www.thesgc.org/about/what_is_the_sgc
2. Open Targets (2016). Overview. https://www.opentargets.org/
3. Sander, J. and Joung, J. (2014). CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology. 32, 347–355.
https://www.ncbi.nlm.nih.gov/pubmed/24584096
4. Innovative Medicines Initiative (2016). Introducing IMI. https://www.imi.europa.eu/content/mission
5. Innovative Medicines Initiative (2016, a).U-BIOPRED: Unbiased biomarkers for the prediction of respiratory disease outcomes. https://www.imi.europa.eu/content/u-biopred 16
9. Animals in research currently play a central role in
discovery and development of new medicines
Annual Statistics of Scientific Procedures on Living Animals Great Britain 2014. https://www.gov.uk/government/statistics/statistics-of-scientific-procedures-on-living-animals-great-britain-2014
17
10. There are approximately 7,000
different rare diseases
worldwide
1in10
individuals in the USA
are living with a rare disease1
Pharmaceutical companies have made
continued advances against rare diseases
1. Rare Diseases A Report on Orphan Drugs in the Pipeline. 2013. America’s Biopharmaceutical Research Companies http://phrma-
docs.phrma.org/sites/default/files/pdf/Rare_Diseases_2013.pdf
2. Pharma R&D Annual Review 2016 Supplement: New Active Substances launched during 2015. https://citeline.com/wp-content/uploads/RD_NAS_2016.pdf
3. EURare Diseases Policy. EUROCAT. http://www.eurocat-network.eu/aboutus/eurarediseasespolicy
Percentage of
New Active
Substances (NAS)
launched with
orphan drug
status 2012-20152
Approximately
246,000 people
In the EU 28 are affected by a rare disease
6% - 8% of the EU population3
18
11. Industry/Academic partnerships are strengthening;
new initiatives are underway
Open Science
Centre for Therapeutic
Target Validation
Harnessing ‘big data’
Welcome Trust, EMBL-EBI
Biogen, GSK
19
12. Industry/Academic partnerships are strengthening;
new initiatives are underway
The Experimental Cancer Medicine Centre combinations alliance –
where CRUK, ECMCs, and industry work together to facilitate testing of
novel combination therapy through investigator led studies
Info here: http://www.ecmcnetwork.org.uk/combinations-alliance-industry
CRUK Stratified medicine programme – a large stratified medicines
lung cancer trial led by CRUK, with treatment supported by AZ and
Pfizer
Info here: http://www.cancerresearchuk.org/funding-for-researchers/how-we-deliver-
research/our-research-partnerships/stratified-medicine-programme
Genomics England – Pharmaceutical companies are working in a
consortium to work with Genomics England to begin to scope how the
data can be used for research into new diagnostics and treatments
Info here: https://www.genomicsengland.co.uk/working-with-industry/
20
13. Sources
Slide Title Source
Medicines and vaccines –have helped deliver improved patient health
and overall survival, slide 9
UCL School of Pharmacy: Affording the Future? The role of cost
effectiveness thresholds in determining NHS patient access to high
quality care in the post-Brexit era.
Improved outcomes for patients, slide 10 Jackman D. January 2016. Page 1. The Value of Pharmaceutical
Products to Patients and the Healthcare System Versus the Cost.
Effective vaccinations have contributed to the fight against
communicable diseases, slide 11
Boccalini 2013 .Economic analysis of the first 20 years of universal
hepatitis B vaccination program in Italy .Human Vaccines &
Immunotherapies
Effective vaccinations have contributed to the fight against
communicable diseases, slide 11
Amirthalingam 2014 .Effectiveness of maternal pertussis vaccination in
England .The Lancet.
Effective vaccinations have contributed to the fight against
communicable diseases, slide 11
Office for National Statistics
Effective vaccinations have contributed to the fight against
communicable diseases, slide 11
National Records of Scotland
Effective vaccinations have contributed to the fight against
communicable diseases, slide 11
Northern Ireland Research and Statistics Agency.
21
14. Slide Title Source
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA.,
slide 12
FDA Novel Drugs 2015 Summary.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves first combination pill to treat hepatitis C 2014
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Novel new drugs summary 2014.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves two drugs, companion diagnostic test for advanced skin
cancer 2013.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves new multiple sclerosis treatment 2013
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves Kalydeco to treat rare form of cystic fibrosis 2012.
Sources
22
15. Slide Title Source
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves Korlym for patients with endogenous Cushing’s
syndrome 2012.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves Benlysta to treat lupus 2011.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves Xalkori with companion diagnostic for a type of late-stage
lung cancer 2011.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves a Cellular Immunotherapy for Men with Advanced
Prostate Cancer 2010.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA approves first oral drug to reduce MS relapses 2010.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves Colchicine for Acute Gout, Mediterranean Fever 2009.
23
Sources
16. Slide Title Source
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves First Drug for Treatment of Peripheral T-cell Lymphoma
2009.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves First Drug for Treatment of Chorea in Huntington's
Disease 2008.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA.,
slide 12
FDA Approves Cimzia to Treat Crohn's Disease 2008.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves First Drug for Treating Fibromyalgia 2007.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves New Beta Blocker to Treat High Blood Pressure 2007.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves the First Once-a-Day Three-Drug Combination Tablet for
Treatment of HIV-1 2006.
24
Sources
17. Slide Title Source
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA,
slide 12
FDA Approves New Treatment for Chest Pain 2006.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA.,
slide 12
FDA Licenses New Vaccine for Prevention of Cervical Cancer and
Other Diseases in Females Caused by Human Papillomavirus 2006.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA.,
slide 12
FDA-Approved Diabetes Medicines 2005.
Pharmaceutical companies around the world
have driven a decade of advances in medicines, as seen in the USA.,
slide 12
FDA Approves New Treatment for Advanced Kidney Cancer 2005.
25
Sources
18. Slide Title Source
The pharmaceutical research and development process takes time, slide 14 Paul S, Nature Reviews Drug Discovery 203-214 (March
2010) | doi:10.1038/nrd3078 In 2010 prices based on Bank of England
exchange rate
The pharmaceutical research and development process takes time, slide 14 Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical
development success rates for investigational drugs. Nat Biotechnol. 2014
Jan 9;32(1):40–51.
The pharmaceutical research and development process takes time, slide 14 Kola I, Landis J. Opinion: Can the pharmaceutical industry reduce attrition
rates? Nat Rev Drug Discov. 2004 Aug;3(8):711–6.
As of 2016 7000 new medicines are in development globally across a
number of different diseases, slide 15
EFPIA. Outcomes-driven sustainable healthcare.
As of 2016 7000 new medicines are in development globally across a
number of different diseases, slide 15
Prescription Medicines: Costs in Context. August 2016.
Discovering new technologies to develop new medicines is central to our
industry, slide 16
Sander, J. and Joung, J. (2014). CRISPR-Cas systems for editing,
regulating and targeting genomes. Nature Biotechnology. 32, 347–355.
Sources
26
19. Slide Title Source
Discovering new technologies to develop new medicines is central to our
industry, slide 16
SGC (2016). Pioneering Science to Inspire Pioneering Medicines
Discovering new technologies to develop new medicines is central to our
industry, slide 16
Open Targets (2016). Overview
Discovering new technologies to develop new medicines is central to our
industry, slide 16
Innovative Medicines Initiative (2016). Introducing IMI
Discovering new technologies to develop new medicines is central to our
industry, slide 16
Innovative Medicines Initiative (2016, a).U-BIOPRED: Unbiased biomarkers
for the prediction of respiratory disease outcomes.
Animals in research currently plays a central role in discovery and
development of new medicines, slide 17
Annual Statistics of Scientific Procedures on Living Animals
Pharmaceutical companies have made
continued advances against rare diseases, slide 18
Rare Diseases A Report on Orphan Drugs in the Pipeline. 2013. America’s
Biopharmaceutical Research Companies.
Pharmaceutical companies have made
continued advances against rare diseases, slide 18
Pharma R&D Annual Review 2016 Supplement: New Active Substances
launched during 2015.
Pharmaceutical companies have made
continued advances against rare diseases, slide 18
EURare Diseases Policy. EUROCAT.
Sources
27